A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance
inhibitor PSC 833 given in combination with paclitaxel. Groups of 3 to 6 patients receive
continuous-infusion paclitaxel for 5 days and oral PSC 833 for 6-7 days, following paclitaxel
on the first course, then beginning 3 days prior to paclitaxel on subsequent courses.
Stable and responding patients are re-treated every 21 days, with paclitaxel dose adjusted to
maintain an absolute neutrophil count less than 500 for no more than 4 days.